https://idataresearch.com/wp-content/uploads/2016/04/ReportIcon-Cell-MS.jpg

Orthobiologics Market Analysis, Size, Trends | Australia | 2020-2026 | Medsuite

  • Year: 2020
  • Scope: 2016-2026
  • Region: Australia
  • Pages: 285
  • Published Date: 07/02/2020
  • Type: MedSuite

By 2020, the Australian orthobiologics market size was valued at $63.8 million, with over 29,000 bone grafting procedures performed every year. The market size is expected to increase at a compound annual growth rate (CAGR) of 4.9% to reach $89.4 million in 2026.

Throughout this medical market research, we analyzed 48 orthobiologics companies across Australia and used our comprehensive methodology to understand the market sizes, unit sales, company market shares, and to create accurate forecasts.

While this MedSuite report contains all of the Australian Orthopedic Biomaterials market data and analysis, each of the market segments is also available as stand-alone MedCore reports. This allows you to get access to only the market research that you need.

DATA TYPES INCLUDED

  • Unit Sales, Average Selling Prices, Market Value & Growth Trends
  • Forecasts Until 2026, and Historical Data to 2016
  • Market Drivers & Limiters for Each Orthopedic Biomaterials Device market
  • Competitive Analysis with Market Shares for Each Segment
  • Recent Mergers & Acquisitions
  • Orthobiologics Procedure Volumes
  • Disease Overviews and Demographic Information
  • Company Profiles, Product Portfolios and SWOT for Top Competitors
  • Related Press Releases from Top Competitors

Market Value and Industry Trends

With some exceptions, tissue supply for allografts and DBM allografts is constrained by the number of available donors. Furthermore, allografts are primarily sold by bone banks in Australia, which is attributed to a relatively high barrier to entry to the market for international companies. As the population ages, there will be a lower supply of eligible bone graft donors.

Australia Orthobiologics Market Size by Segment, 2016-2026

Surgical procedures that require the use of orthopedic biomaterials are generally associated with diseases and indications that become more prevalent in the population with an increase in age, such as osteoarthritis of the spine and knee. In 2019, over 15% of Australians were aged 65 and over; this proportion is projected to grow steadily over the forecast period, as further cohorts of baby boomers turn 65.

Single-injection HA viscosupplementation products are relatively new to the Australian market. In 2019, there were three single-injection products available: Sanofi’s Synvisc-One®, Bioventus’ Durolane® and Anika Therapeutics’ MONOVISC®. Although three-injection products were available in Australia before single-injection products, the benefits of the latter are typically perceived to outweigh the favorable cost of the former. As a result, single-injection products are expected to> continue to cannibalize three-injection products over the forecast period.

Competitive Analysis

Australia Orthopedic Biomaterials Market Leaders

By 2020, the leading competitor in the Australian orthopedic biomaterials market was Medtronic. The company has established this role through strong performance of its growth factor product line, INFUSE®, which first entered the market in 2006. Medtronic also held a notable position in the DBM allograft and synthetic markets.

DePuy Synthes was the second-leading competitor in the Australian market, which was solely attributed to its leading position in the orthopedic bone graft substitute market. The company was particularly strong in the DBM allograft market, which continues to be the fastest-growing bone graft substitute segment.

Other notable competitors included, but were not limited to, Stryker, bone banks, Wright Medical, Cerapedics, Sanofi, Bioventus and Anika Therapeutics. Unlike the bone graft substitute market, which is heavily fragmented, the orthopedic graft factor and HA viscosupplementation markets are controlled by a smaller number of companies.

Segments Covered

Click on each title to view more detailed market segmentation.

  • Procedure Volumes for Orthopedic Biomaterials DevicesMedPro – The Complete procedural analysis for each segment of the Australian Orthopedic Biomaterials market.
  • Orthopedic Bone Graft Substitute Market – MedCore – This market is further segmented by Material Type, including Allograft, Demineralized Bone Matrix Allograft, and Synthetic. Each of these Material Types are segmented by Spine, Trauma, Large Joint Reconstruction, Craniomaxillofacial, and Oncology.
  • Orthopedic Growth Factor Market – MedCore – In-depth analysis of the Orthopedic Growth Factor market.
  • Hyaluronic Acid Viscosupplementation Market – MedCore – This market is categorized by Treatment Type, including Single-Injection and Three-Injection.

Detailed Market Segmentation

DON’T SEE THE SEGMENT OR DATA YOU NEED?

Feel free to contact us or send a request by pressing one of the buttons below.

TABLE OF CONTENTS FOR THE AUSTRALIAN ORTHOPEDIC BIOMATERIALS MARKET REPORT SUITE

TABLE OF CONTENTS I
LIST OF FIGURES VIII
LIST OF CHARTS XV
EXECUTIVE SUMMARY 1
AUSTRALIAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW 1
COMPETITIVE ANALYSIS 3
MARKET TRENDS 5
MARKET DEVELOPMENTS 6
PROCEDURE NUMBERS 7
MARKETS INCLUDED 8
KEY REPORT UPDATES 10
VERSION HISTORY 10
RESEARCH METHODOLOGY 11
Step 1: Project Initiation & Team Selection 11
Step 2: Prepare Data Systems and Perform Secondary Research 14
Step 3: Preparation for Interviews & Questionnaire Design 16
Step 4: Performing Primary Research 17
Step 5: Research Analysis: Establishing Baseline Estimates 19
Step 6: Market Forecast and Analysis 20
Step 7: Identify Strategic Opportunities 22
Step 8: Final Review and Market Release 23
Step 9: Customer Feedback and Market Monitoring 24

PRODUCT ASSESSMENT

2.1 INTRODUCTION 25
2.2 PRODUCT PORTFOLIOS 25
2.2.1 Bone Graft Substitutes 26
2.2.2 Growth Factors 32
2.2.2.1 Other products 35
2.2.3 Hyaluronic Acid Viscosupplementation (HAV) 37
2.3 REGULATORY ISSUES AND RECALLS 40
2.3.1 Bone Graft Substitutes 40
2.3.1.1 Allografts 40
2.3.1.1.1 MTF 40
2.3.1.2 DBM 40
2.3.1.2.1 AlloSource 40
2.3.1.2.2 SeaSpine 41
2.3.1.2.3 RTI Surgical 41
2.3.1.3 Synthetics 41
2.3.1.3.1 Abyrx 41
2.3.1.3.2 Zimmer Biomet 42
2.3.2 Growth Factors 42
2.3.2.1.1 Medtronic 42
2.3.3 Hyaluronic Acid Viscosupplementation 43
2.3.3.1 Three-injection 43
2.3.3.1.1 Ferring Pharmaceuticals 43
2.4 CLINICAL TRIALS 44
2.4.1 Bone Graft Substitutes 44
2.4.1.1 Allografts 44
2.4.1.1.1 Providence Medical Technology 44
2.4.1.1.2 The University of Texas Health Science 44
2.4.1.1.3 University of Winchester 45
2.4.1.2 BDM 45
2.4.1.2.1 K2M 45
2.4.1.2.2 Zimmer Biomet 46
2.4.1.3 Synthetics 46
2.4.1.3.1 Baxter 46
2.4.1.3.2 Bonesupport 47
2.4.1.3.3 DePuy Synthes 47
2.4.1.3.4 NuVasive 49
2.4.1.3.5 RTI surgical 49
2.4.1.3.6 Sunstar GUIDOR 50
2.4.1.4 Other materials and comparison 51
2.4.1.4.1 Seoul National University Hospital. 51
2.4.1.4.2 Sewon Cellontech 51
2.4.1.4.3 SurgaColl Technologies Limited 52
2.4.1.4.4 University of Colorado 52
2.4.1.4.5 University of Padova 53
2.4.2 Growth Factors 53
2.4.2.1.1 Bioventus 53
2.4.2.1.2 Cerapedics 54
2.4.2.1.3 CGBio 54
2.4.2.1.4 Isto 55
2.4.2.1.5 Medtronic 55
2.4.2.1.6 NuVasive 57
2.4.2.1.7 Wright 57
2.4.2.1.8 Others 58
2.4.3 Hyaluronic Acid Viscosupplementation 59
2.4.3.1.1 Anika Therapeutics 59
2.4.3.1.2 Bioventus 60
2.4.3.1.3 Cario University 61
2.4.3.1.4 Ferring Pharmaceuticals 61
2.4.3.1.5 Federal University of Minas Gerais 62
2.4.3.1.6 Fidia Pharma USA Inc. 62
2.4.3.1.7 Istituto Ortopedico Rizzoli 63
2.4.3.1.8 University Hospital 63
2.4.3.1.9 Universidade Nova de Lisboa 64

AUSTRALIAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW

3.1 INTRODUCTION 65
3.1.1 Bone Graft Substitutes 65
3.1.2 Growth Factors 65
3.1.3 Hyaluronic Acid (HA) Viscosupplementation 66
3.2 CURRENCY EXCHANGE RATE 67
3.3 MARKET OVERVIEW AND TREND ANALYSIS 68
3.4 DRIVERS AND LIMITERS 76
3.4.1 Market Drivers 76
3.4.2 Market Limiters 76
3.5 COMPETITIVE MARKET SHARE ANALYSIS 78
3.6 MERGERS AND ACQUISITIONS 84
3.7 COMPANY PROFILES 86
3.7.1 Anika Therapeutics 86
3.7.2 Bioventus 87
3.7.3 DePuy Synthes 88
3.7.4 Ferring Pharmaceuticals 89
3.7.5 Fidia Pharmaceuticals 90
3.7.6 Genzyme (Sanofi Group) 91
3.7.7 Harvest Technologies (Terumo BCT) 92
3.7.8 Integra LifeSciences 93
3.7.9 Medtronic 94
3.7.10 Musculoskeletal Transplant Foundation (MTF) 96
3.7.11 NuVasive 97
3.7.12 Orthofix 98
3.7.13 RTI Surgical 99
3.7.14 Stryker 100
3.7.15 Vericel Corporation (formerly Aastrom Bioscience) 101
3.7.16 Zimmer Biomet 102
3.8 SWOT ANALYSIS 104
3.8.1 Anika Therapeutics 104
3.8.2 Bioventus 106
3.8.3 DePuy Synthes 108
3.8.4 Ferring Pharmaceuticals 109
3.8.5 Fidia Pharmaceuticals 110
3.8.7 Harvest Technologies (Terumo BCT) 112
3.8.8 Integra LifeSciences 113
3.8.9 Medtronic 114
3.8.10 Musculoskeletal Transplant Foundation (MTF) 115
3.8.11 NuVasive 116
3.8.12 Orthofix 117
3.8.14 Stryker 119
3.8.15 Vericel Corporation (formerly Aastrom Bioscience) 120
3.8.16 Zimmer Biomet 121

PROCEDURE NUMBERS

4.1 INTRODUCTION 123
4.2 PROCEDURES 124
4.2.1 Orthopedic Biomaterial Procedures by Segment 124
4.2.2 Orthopedic Bone Grafting Procedures 126
4.2.2.1 Units per Procedure by Indication 126
4.2.2.2 Orthopedic Bone Grafting Procedures by Material 127
4.2.2.2.1 Autograft Procedures by Indication 129
4.2.2.2.2 Allograft Procedures by Indication 132
4.2.2.2.3 DBM Allograft Procedures by Indication 135
4.2.2.2.4 Synthetic Procedures by Indication 138
4.2.2.3 Orthopedic Bone Grafting Procedures by Indication 141
4.2.3 Orthopedic Growth Factor Procedures 144
4.2.4 Hyaluronic Acid Supplementation Procedures 146
4.2.4.1 Hyaluronic Acid Supplementation Procedures by Injection Cycle 146

ORTHOPEDIC BONE GRAFT SUBSTITUTE MARKET

5.1 INTRODUCTION 148
5.2 MARKET OVERVIEW 149
5.2.1 Orthopedic Bone Graft Substitute Market by Material 149
5.2.2 Orthopedic Bone Graft Substitute Market by Indication 154
5.3 MARKET ANALYSIS AND FORECAST 160
5.3.1 Total Orthopedic Bone Graft Substitute Market 160
5.3.2 Orthopedic Bone Graft Substitute Market by Material 162
5.3.2.1 Allograft Bone Graft Substitute Market 162
5.3.2.1.1 Allograft Bone Graft Substitute Market by Indication 164
5.3.2.2 Demineralized Bone Matrix Allograft Bone Graft Substitute Market 178
5.3.2.2.1 Demineralized Bone Matrix Allograft Bone Graft Substitute Market by Indication 180
5.3.2.3 Synthetic Bone Graft Substitute Market 194
5.3.2.3.1 Synthetic Bone Graft Substitute Market by Indication 196
5.3.3 Orthopedic Bone Graft Substitute Market by Indication 210
5.3.3.1 Spine Bone Graft Substitute Market 210
5.3.3.2 Cervical Spine Bone Graft Substitute Market 212
5.3.3.3 Thoracolumbar Spine Bone Graft Substitute Market 214
5.3.3.4 Trauma Bone Graft Substitute Market 216
5.3.3.5 Non-Union Trauma Bone Graft Substitute Market 218
5.3.3.6 Fresh Fracture Trauma Bone Graft Substitute Market 220
5.3.3.7 Large Joint Reconstruction Bone Graft Substitute Market 222
5.3.3.8 Hip Reconstruction Bone Graft Substitute Market 224
5.3.3.9 Knee Reconstruction Bone Graft Substitute Market 226
5.3.3.10 Foot Reconstruction Bone Graft Substitute Market 228
5.3.3.11 Craniomaxillofacial Bone Graft Substitute Market 230
5.3.3.12 Oncology Bone Graft Substitute Market 232
5.4 DRIVERS AND LIMITERS 234
5.4.1 Market Drivers 234
5.4.2 Market Limiters 234
5.5 COMPETITIVE MARKET SHARE ANALYSIS 236

ORTHOPEDIC GROWTH FACTOR MARKET

6.1 INTRODUCTION 240
6.1.1 BMP-2 (Medtronic) 241
6.1.2 PDGF-BB (Wright Medical) 241
6.1.3 P-15 Synthetic Small Peptide (Cerapedics) 241
6.1.4 P-15 Synthetic Small Peptide (Biocomposites) 241
6.2 MARKET ANALYSIS AND FORECAST 242
6.3 DRIVERS AND LIMITERS 244
6.3.1 Market Drivers 244
6.3.2 Market Limiters 244
6.4 COMPETITIVE MARKET SHARE ANALYSIS 246

HYALURONIC ACID VISCOSUPPLEMENTATION MARKET

7.1 INTRODUCTION 249
7.1.1 Benefits of Viscosupplementation 250
7.1.2 Synovial Fluid 250
7.2 MARKET OVERVIEW 251
7.3 MARKET ANALYSIS AND FORECAST 257
7.3.1 Total Hyaluronic Acid Viscosupplementation Market 257
7.3.2 Single-Injection Hyaluronic Acid Viscosupplementation Market 259
7.3.3 Three-Injection Hyaluronic Acid Viscosupplementation Market 261
7.4 DRIVERS AND LIMITERS 263
7.4.1 Market Drivers 263
7.4.2 Market Limiters 263
7.5 COMPETITIVE MARKET SHARE ANALYSIS 265

ABBREVIATIONS

The Orthobiologics Market Report Suite | Australia | 2020-2026 | MedSuite includes analysis on the following companies currently active in this market:

  • Alphatec
  • Anika Therapeutics
  • Arthrex
  • Australian Biotechnologies
  • Australian Tissue Donation Network
  • B. Braun
  • Barwon Health Bone Bank
  • Baxter
  • Biocomposites
  • Bioventus
  • Cerapedics
  • Corin
  • DePuy Synthes
  • Donor Tissue Bank of Victoria
  • Finceramica
  • Globus Medical
  • Hunter New England and Local Health District
  • Hunter New England Bone Bank
  • Institute of Medical & Veterinary Science
  • Joy Surgical
  • JRI Orthopaedics
  • Kasios
  • LifeHealthcare
  • LMT Surgical
  • Alphatec
  • Anika Therapeutics
  • Arthrex
  • Australian Biotechnologies
  • Australian Tissue Donation Network
  • B. Braun
  • Barwon Health Bone Bank
  • Baxter
  • Biocomposites
  • Bioventus
  • Cerapedics
  • Corin
  • DePuy Synthes
  • Donor Tissue Bank of Victoria
  • Finceramica
  • Globus Medical
  • Hunter New England and Local Health District
  • Hunter New England Bone Bank
  • Institute of Medical & Veterinary Science
  • Joy Surgical
  • JRI Orthopaedics
  • Kasios
  • LifeHealthcare
  • LMT Surgical

iData’s 9-Step Research Methodology

Our reports follow an in-depth 9-step methodology which focuses on the following research systems:

  • Original primary research that consists of the most up-to-date market data
  • Strong foundation of quantitative and qualitative research
  • Focused on the needs and strategic challenges of the industry participants

Step 1: Project Initiation & Team Selection During this preliminary investigation, all staff members involved in the industry discusses the topic in detail.

Step 2: Prepare Data Systems and Perform Secondary Research The first task of the research team is to prepare for the data collection process: Filing systems and relational databases are developed as needed.

Step 3: Preparation for Interviews & Questionnaire Design The core of all iData research reports is primary market research. Interviews with industry insiders represent the single most reliable way to obtain accurate, current data about market conditions, trends, threats and opportunities.

Step 4: Performing Primary Research At this stage, interviews are performed using contacts and information acquired in the secondary research phase.

Step 5: Research Analysis: Establishing Baseline Estimates Following the completion of the primary research phase, the collected information must be synthesized into an accurate view of the market status. The most important question is the current state of the market.

Step 6: Market Forecast and Analysis iData Research uses a proprietary method to combine statistical data and opinions of industry experts to forecast future market values.

Step 7: Identify Strategic Opportunities iData analysts identify in broad terms why some companies are gaining or losing share within a given market segment.

Step 8: Final Review and Market Release An integral part of the iData research methodology is a built-in philosophy of quality control and continuing improvement is integral to the iData philosophy.

Step 9: Customer Feedback and Market Monitoring iData philosophy of continuous improvement requires that reports and consulting projects be monitored after release for customer feedback and market accuracy.

Click Here to Read More About Our Methodology